The main customers of traditional bioreactors are research labs and the pharmaceutical industry ... growing cells without any knowledge of the biological details involved,” he says.

Biologics contract manufacturing, or BCM, refers to the collaboration between a pharmaceutical company ... cell culture, and bioreactor operations Downstream processing – purification ...

The pharmaceutical manufacturing equipment market is projected to grow at a CAGR of 6-8% during the forecast period. Growth ...

Schematic of a typical bioreactor. Key components include the reactor tank, agitation system, feeding pump, thermal jacket, submerged aerator, and sensor probes for monitoring and maintaining optimal ...

The agreement is valued at over $3 billion and increases U.S. manufacturing capacity to help ensure patient access to ...

This is particularly true for biologic agents such as neutralizing antibodies, which must be produced via a complex and labour-intensive process that begins with big bioreactor tanks of protein ...

CDMO, AGC Biologics, announced a strategic decision about the large-scale single-use technology it will use at its new Yokohama, Japan facility. The company added two 5,000 L Thermo Scientific ...

Unlike its global peers, WuXi specializes in biologic therapeutic modalities. It has one of the largest bioreactor capacities ... much faster than global pharmaceutical sales or global CDMOs.